BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Merck & Co., Inc. (MRK) Shelves Development of Another Diabetes-Cholesterol Program


11/13/2012 10:43:46 AM

Merck MRK +0.09% & Co. halted development of a pill combining its diabetes drug Januvia with a generic version of the widely used cholesterol fighter Lipitor, citing unspecified business reasons. The Whitehouse Station, N.J., company discontinued development of MK-0431E, which Merck had previously planned to submit for regulatory approval in 2014. Merck spokeswoman Pam Eisele said Tuesday the decision isn't related to any safety concerns about the two drugs. It is the second time in recent months that Merck has stopped development of a combination drug that includes a cholesterol treatment. Merck also has abandoned MK-0524B, a drug that included niacin and simvastatin, saying market conditions had become less favorable. Januvia, which contains the active ingredient sitagliptin, is Merck's best-selling drug, generating $2.95 billion in sales for the first nine months of this year. It is a once-daily tablet to treat Type 2 diabetes by helping to lower blood-sugar levels. Since Januvia went on sale in 2006, Merck has introduced new products combining it with other drugs. Last year, for instance, the U.S. Food and Drug Administration approved Juvisync, a single-pill combination of Januvia and simvastatin, a so-called statin drug that lowers bad cholesterol.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES